CD274 and hepatocellular carcinoma: In addition, atezolizumab, which selectively targets PD-L1 and reserves T-cell suppression, plus bevacizumab, which targets vascular endothelial growth factor and inhibits angiogenesis, was compared with sorafenib in the treatment of unresectable HCC (58).